| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 213.56% | Alliance Global Partners | → $1.85 | Initiates Coverage On | → Buy |
| 08/18/2023 | 408.47% | Lake Street | $2 → $3 | Maintains | Buy |
| 07/21/2023 | 916.95% | Roth MKM | $1 → $6 | Maintains | Buy |
| 05/02/2023 | 238.98% | Lake Street | → $2 | Initiates Coverage On | → Buy |
| 09/12/2022 | 1255.93% | Aegis Capital | $10 → $8 | Maintains | Buy |
| 09/02/2022 | 408.47% | Roth MKM | $6 → $3 | Maintains | Buy |
| 10/08/2021 | 1086.44% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 07/29/2021 | 1594.92% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 12/01/2020 | 1425.42% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
What is the target price for Evogene (EVGN)?
The latest price target for Evogene (NASDAQ: EVGN) was reported by Alliance Global Partners on October 2, 2023. The analyst firm set a price target for $1.85 expecting EVGN to rise to within 12 months (a possible 213.56% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evogene (EVGN)?
The latest analyst rating for Evogene (NASDAQ: EVGN) was provided by Alliance Global Partners, and Evogene initiated their buy rating.
When is the next analyst rating going to be posted or updated for Evogene (EVGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evogene was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
Is the Analyst Rating Evogene (EVGN) correct?
While ratings are subjective and will change, the latest Evogene (EVGN) rating was a initiated with a price target of $0.00 to $1.85. The current price Evogene (EVGN) is trading at is $0.59, which is within the analyst's predicted range.